Overview

A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
This study will determine the appropriate dose and frequency of administration of iv Mircera maintenance therapy in hemodialysis patients with chronic renal anemia who were previously receiving iv epoetin. The anticipated time on study treatment is 3-12 months and the target sample size is <100 individuals.
Phase:
Phase 2
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Epoetin Alfa